TARGET-EU: Clinical benefit of bevacizumab in metastatic colorectal cancer

Data sources

• Data source(s):
  Netherlands Cancer Registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

CDM Mappings

• CDM name:
  OMOP
• CDM website:
  https://www.ohdsi.org/Data-standardization/

• CDM version:
  v5.4

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Yes
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  Yes
• Data characterisation details:
  The feasibility assessment for this case study, detailed in the appendix of the study protocol, was conducted as part of the broader TARGET-EU feasibility assessment (EUPAS1000000791). Data source suitability was evaluated using a structured framework based on the EMA data quality framework, assessing system characteristics, data quality, and fitness for the research question.; ; Briefly, the NCR was deemed a feasible data source for studying CapOx(-B) and PFS, with achievable sample sizes and reasonably up-to-date data. The database provides reliable in- and outpatient hospital data and timely updates, but some limitations were identified. For instance, PFS is not captured in the NCR through medical imaging directly, but through a validated algorithm that marks the end of “episodes”, as previously discussed. The missingness in ECOG PS will not have much impact, since ECOG PS is one of the inclusion criteria.

Data characterisation results

Feasibility assessment CS10.pdf